IS7999A - Prostaglandín hliðstæður sem EP4 viðtaka mótlyf - Google Patents

Prostaglandín hliðstæður sem EP4 viðtaka mótlyf

Info

Publication number
IS7999A
IS7999A IS7999A IS7999A IS7999A IS 7999 A IS7999 A IS 7999A IS 7999 A IS7999 A IS 7999A IS 7999 A IS7999 A IS 7999A IS 7999 A IS7999 A IS 7999A
Authority
IS
Iceland
Prior art keywords
receptor antagonist
prostaglandin analogues
prostaglandin
analogues
antagonist
Prior art date
Application number
IS7999A
Other languages
English (en)
Inventor
Billot Xavier
Colucci John
Han Yongxin
Wilson Marie-Claire
N. Young Robert
Original Assignee
Merck Frosst Canada Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd. filed Critical Merck Frosst Canada Ltd.
Publication of IS7999A publication Critical patent/IS7999A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IS7999A 2003-03-26 2005-08-25 Prostaglandín hliðstæður sem EP4 viðtaka mótlyf IS7999A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45770003P 2003-03-26 2003-03-26
PCT/CA2004/000471 WO2004085431A1 (en) 2003-03-26 2004-03-26 Prostaglandin analogs as ep4 receptor antagonists

Publications (1)

Publication Number Publication Date
IS7999A true IS7999A (is) 2005-08-25

Family

ID=33098243

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7999A IS7999A (is) 2003-03-26 2005-08-25 Prostaglandín hliðstæður sem EP4 viðtaka mótlyf

Country Status (22)

Country Link
US (4) US7053085B2 (is)
EP (1) EP1613621B1 (is)
JP (1) JP4866992B2 (is)
KR (1) KR20060002873A (is)
CN (1) CN1764659A (is)
AR (1) AR040806A1 (is)
AT (1) ATE474837T1 (is)
BR (1) BRPI0408690A (is)
CA (1) CA2519938C (is)
CL (1) CL2004000655A1 (is)
DE (1) DE602004028229D1 (is)
EC (1) ECSP056037A (is)
ES (1) ES2347434T3 (is)
HR (1) HRP20050845A2 (is)
IS (1) IS7999A (is)
MA (1) MA27667A1 (is)
MX (1) MXPA05010189A (is)
NO (1) NO20054951L (is)
PE (1) PE20050522A1 (is)
RU (1) RU2005132930A (is)
TW (1) TW200427670A (is)
WO (2) WO2004085431A1 (is)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
JP2006515015A (ja) * 2003-01-10 2006-05-18 エフ．ホフマン−ラ　ロシュ　アーゲー プロスタグランジンアゴニストとしての２−ピペリドン誘導体
US6977260B2 (en) 2004-01-22 2005-12-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7326716B2 (en) 2003-06-06 2008-02-05 Allergan, Inc. Treatment of inflammatory bowel disease
EP1631355B1 (en) * 2003-06-06 2014-08-13 Allergan, Inc. Piperidinyl prostaglandin e analogs
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
AU2004268012B2 (en) 2003-09-02 2008-11-20 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
AU2004272546B2 (en) 2003-09-04 2007-10-18 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
JP2007504236A (ja) 2003-09-04 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症を治療するための眼用組成物
CA2571786A1 (en) 2004-07-02 2006-02-09 Allergan, Inc. Prostaglandin analogs
AU2005274972A1 (en) * 2004-07-20 2006-02-23 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CA2585367A1 (en) * 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US7994195B2 (en) * 2004-11-04 2011-08-09 Allergan, Inc. Therapeutic substituted piperidone compounds
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
KR100890490B1 (ko) * 2005-01-27 2009-03-26 아사히 가세이 파마 가부시키가이샤 헤테로 6원환 화합물 및 그의 용도
EP1912957A4 (en) * 2005-08-03 2009-05-13 Merck Frosst Canada Ltd EP4 AGONIST RECEIVER, COMPOSITIONS AND METHODS RESULTING THEREFROM
WO2007014454A1 (en) * 2005-08-03 2007-02-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
US7498447B2 (en) 2006-05-24 2009-03-03 Allergan, Inc. Therapeutic compounds
US7550448B2 (en) 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
WO2008027341A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
CA2666972C (en) 2006-10-20 2015-12-29 Children's Medical Center Corporation Method to enhance tissue regeneration
CN101168514B (zh) * 2006-10-26 2011-12-07 上海药明康德新药开发有限公司 光学活性α-氨基辛二酸酯和α-氨基辛二酸单酯的合成方法
CA2672631A1 (en) 2006-12-15 2008-06-19 Glaxo Group Limited Benzamide derivatives as ep4 receptor agonists
GB2446652A (en) * 2007-02-16 2008-08-20 Inion Ltd Osteogenic compounds
WO2008136519A1 (ja) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Ｅｐ４アゴニストを含有してなる細胞傷害性ｔ細胞の活性化剤
WO2008149965A1 (ja) * 2007-06-07 2008-12-11 Astellas Pharma Inc. ピリドン化合物
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
CN101468985A (zh) * 2007-12-28 2009-07-01 中国人民解放军军事医学科学院毒物药物研究所 5-(3-芳杂环取代苯基)四氮唑类化合物及其抗hiv/aids的应用
US8633310B2 (en) 2008-02-19 2014-01-21 Allergan, Inc. Therapeutic substituted lactams
US7964596B2 (en) 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
US20120190637A1 (en) 2009-10-14 2012-07-26 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
CA2738045C (en) * 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
MX2016001714A (es) 2013-08-09 2016-10-03 Ardelyx Inc Compuestos y metodos para inhibir el transporte de fosfato.
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
CN107849072B (zh) 2015-06-12 2020-12-15 西蒙弗雷泽大学 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
WO2017126635A1 (ja) * 2016-01-22 2017-07-27 武田薬品工業株式会社 複素環化合物およびその用途
CN111511736B (zh) 2017-12-25 2023-03-24 旭化成制药株式会社 含氮6元环化合物
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport
CN111269193B (zh) * 2020-04-02 2022-05-24 湖南海利常德农药化工有限公司 一种苯并[e][1,3]噁嗪-2,4-二酮的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524818A (en) 1974-11-29 1978-09-13 Beecham Group Ltd 12-azaprostaglandins
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
EP0008186A1 (en) 1978-08-08 1980-02-20 Beecham Group Plc Cyclic diamides, a process for their preparation and their pharmaceutical compositions
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
US4960771A (en) * 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP0569046B1 (en) 1988-09-06 2002-11-13 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
US6586468B1 (en) 1998-09-14 2003-07-01 Ono Pharmaceutical Co., Ltd. ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient
EP1121133A1 (en) 1998-10-15 2001-08-08 Merck & Co., Inc. Methods for stimulating bone formation
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
AP2002002555A0 (en) 1999-12-22 2002-06-30 Pfizer Prod Inc EP4 Receptor selective agonists in the treatment of osteoporosis.
CN1450994A (zh) 2000-03-17 2003-10-22 爱尔康公司 用于治疗青光眼的6－羟基－吲唑衍生物
EP1186287A1 (en) 2000-03-31 2002-03-13 Toray Industries, Inc. Hair growth or hair formation controlling agents
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
CN1476429A (zh) 2000-11-27 2004-02-18 �Ʒ� 治疗骨质疏松的ep4受体选择性激动剂
CA2434495A1 (en) 2001-01-30 2002-08-08 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1373545A4 (en) 2001-03-22 2005-07-20 Merck & Co Inc MICE WITH MCH1R LACK
WO2003047417A2 (en) 2001-12-03 2003-06-12 Merck & Co., Inc. Ep4 receptor agonist, compositions and methods thereof
CA2466757A1 (en) 2001-12-03 2003-06-12 Merck & Co., Inc. Method for treating ocular hypertension
AU2003239972B2 (en) 2002-06-14 2008-02-28 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP2005533055A (ja) 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド 新規マキシｋチャンネルブロッカー、その使用方法および製造方法
AU2003245531A1 (en) 2002-06-17 2003-12-31 Merck & Co., Inc. Novel maxi-k channel blockers, methods of use and process for making the same
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
JP2006515015A (ja) * 2003-01-10 2006-05-18 エフ．ホフマン−ラ　ロシュ　アーゲー プロスタグランジンアゴニストとしての２−ピペリドン誘導体
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs

Also Published As

Publication number Publication date
ECSP056037A (es) 2006-01-27
JP2006520758A (ja) 2006-09-14
EP1613621B1 (en) 2010-07-21
US20040198701A1 (en) 2004-10-07
AR040806A1 (es) 2005-04-20
MXPA05010189A (es) 2006-02-22
CN1764659A (zh) 2006-04-26
JP4866992B2 (ja) 2012-02-01
US20050227969A1 (en) 2005-10-13
HRP20050845A2 (en) 2006-05-31
AU2004224261A1 (en) 2004-10-07
DE602004028229D1 (de) 2010-09-02
ATE474837T1 (de) 2010-08-15
TW200427670A (en) 2004-12-16
CA2519938C (en) 2010-11-30
BRPI0408690A (pt) 2006-03-28
US7053085B2 (en) 2006-05-30
NO20054951L (no) 2005-12-22
WO2004085431A1 (en) 2004-10-07
RU2005132930A (ru) 2006-02-10
CA2519938A1 (en) 2004-10-07
ES2347434T3 (es) 2010-10-29
NO20054951D0 (no) 2005-10-25
US20110237511A1 (en) 2011-09-29
MA27667A1 (fr) 2005-12-01
USRE42562E1 (en) 2011-07-19
PE20050522A1 (es) 2005-07-06
CL2004000655A1 (es) 2005-01-21
EP1613621A1 (en) 2006-01-11
KR20060002873A (ko) 2006-01-09
WO2004085430A1 (en) 2004-10-07
US7238710B2 (en) 2007-07-03

Similar Documents

Publication Publication Date Title
IS7999A (is) Prostaglandín hliðstæður sem EP4 viðtaka mótlyf
IS8117A (is) 3-Flúr-píperidín sem NMDA/NR2B mótlyf
IS8501A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
IS8199A (is) Afleiður (þíó) karbamóýl-sýklóhexans sem mótlyf D3/D2 viðtaka
IS7874A (is) Ímídasókínólínafleiður sem adenósín A3 viðtakabindlar
IS8345A (is) 6-útskipt anilínópúrín sem RTK-tálmar
DK1819670T3 (da) 12-Aryl-prostaglandinanaloger
IS2756B (is) Samrunnin heteróhringssambönd sem stillar fyrir viðtaka serótóníns
SG158918A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
SG156653A1 (en) 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists
EP1845972A4 (en) CANNAPINOID RECEPTORS APPLYING NOVEL HETEROPYRROL ANALOGS
NO20054669D0 (no) Substituerte kinobenzoxazinanaloger
CY2013035I1 (el) Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδεσμευσης
ATE382034T1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
IS8039A (is) Asýlaðar spírópíperidín afleiður sem melanókortín-4 viðtaka gerandefni
IS8291A (is) Pýrról-2,5-tvíþíónafleiður sem lifrar X viðtakastillar
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
HK1093070A1 (en) Imidazole derivatives as glutamate receptor antagonists
DK1781618T3 (da) Sigma-receptorinhibitorer
DK1660090T3 (da) Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
HUP0600858A2 (en) Piperizinyilpiperidine derivatives as chemokine receptor antagonists
DE602005001661D1 (de) Vermessungsgerät
IS8278A (is) Sýkóprópýl afleiður sem NK3 viðtaka mótlyf
HK1099203A1 (en) Piperidinyl prostaglandin e analogs
ITMI20042239A1 (it) Additivi per fluoropolieterei